Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis

Liam, CK; Ahmad, AR; Hsia, TC; Zhou, JY; Kim, DW; Soo, RA; Cheng, Y; Lu, S; Shin, SW; Yang, JCH; Zhang, YP; Zhao, J; Berghoff, K; Bruns, R; Johne, A; Wu, YL

Wu, YL (通讯作者)，Guangdong Prov Peoples Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China.;Wu, YL (通讯作者)，Guangdong Acad Med Sci, Guangzhou 510080, Guangdong, Peoples R China.

CLINICAL CANCER RESEARCH, 2023; 29 (10): 1879

Abstract

Purpose: The final analyses of the INSIGHT phase II study evaluating tepotinib (a selective MET inhibitor) plus gefitinib versus chemotherapy in patie......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索